Dr. Ruchika Talwar

We can pivot.

Or if we get more data in the future, that swings us one way or another.

So I think that's a great point.

In terms of the conversation as it relates to counseling regarding long-term outcomes and metastatic risk, you know, you covered the PROTECT data as we started off this conversation.

Is that what you use in your counseling or are you referencing some of these other studies?

Again, probably more centered in the low-risk space, but what can we extrapolate and what's more relevant for this population?

Yeah.

And speaking of which, what are you most excited about in the future as more and more people are thinking about this question?

Are there studies that are ongoing that you're looking forward to being able to guide some of these conversations in the clinic?

Yeah, I think the liquid biopsies are really, really interesting, right?

Because we didn't cover this, but let's not forget, one of the big reasons patients opt against active surveillance is the need for repeated prostate biopsies.

It is not something they enjoy.

There are side effects, transient erectile dysfunction, the discomfort of having blood in your urine, semen stool, the pain.

If you're having it in the office, the fact that it's just an uncomfortable, anxiety-provoking experience.

And so I think looking to the future, I get really excited about the fact that we are trying to better diagnose cancer.

prostate cancer better, more accurately, I'll put it that way, but also with less invasive, less uncomfortable techniques.

Because I think the elephant in the room is that it is, you know, in its current form, it is really not the most patient-centric experience.

Yeah, absolutely.

Couldn't agree more.

Couldn't agree more.